Search results
Found 12434 matches for
Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
©
John Cairns
Carcinoma in situ presented at EuropaDonna
Work on breast carcinoma in situ was discussed with members of the patient advocate organisation, EuropaDonna in October 2024.